Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Nigel Greig
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Living Beings
Disorders
Anatomy
Concepts & Ideas
Physiology
Sign-in to see full Profile
Network (preview)
37
Lahiri, Debomoy
35
Holloway, Harold
26
Yu, Qian-Sheng
25
Rapoport, Stanley
21
Brossi, Arnold
16
Sambamurti, Kumar
16
Ingram, Donald
15
Perry, TracyAnn
13
Utsuki, Tada
12
Egan, Josephine
11
Mattson, Mark
10
Rogers, Jack
9
Spangler, Edward
9
Tweedie, David
9
Giordano, Tony
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Nigel Greig (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Tweedie David; Luo Weiming; Short Ryan G; Brossi Arnold; Holloway Harold W; Li Yazhou; Yu Qian-sheng; Greig Nigel H
A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors.
Journal of neuroscience methods 2009;183(2):182-7.
-
2009: Wang Yue; Greig Nigel H; Yu Qian-sheng; Mattson Mark P
Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices.
Neurobiology of aging 2009;30(7):1061-8.
-
2009: Luo Yu; Kuo Chi-Chung; Shen Hui; Chou Jenny; Greig Nigel H; Hoffer Barry J; Wang Yun
Delayed treatment with a p53 inhibitor enhances recovery in stroke brain.
Annals of neurology 2009;65(5):520-30.
-
2009: Olivares David; Huang Xudong; Branden Lars; Greig Nigel H; Rogers Jack T
Physiological and Pathological Role of Alpha-synuclein in Parkinson's Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element.
International journal of molecular sciences 2009;10(3):1226-60.
-
2009: Becker Robert E; Unni Latha K; Greig Nigel H
Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.
Current Alzheimer research 2009;6(1):79-81.
-
2009: Becker Robert E; Greig Nigel H
Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?
Journal of clinical psychopharmacology 2009;29(1):56-64.
-
2009: Martin Bronwen; Golden Erin; Carlson Olga D; Pistell Paul; Zhou Jie; Kim Wook; Frank Brittany P; Thomas Sam; Chadwick Wayne A; Greig Nigel H; Bates Gillian P; Sathasivam Kirupa; Bernier Michel; Maudsley Stuart; Mattson Mark P; Egan Josephine M
Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.
Diabetes 2009;58(2):318-28.
-
2009: Li Yazhou; Perry TracyAnn; Kindy Mark S; Harvey Brandon K; Tweedie David; Holloway Harold W; Powers Kathleen; Shen Hui; Egan Josephine M; Sambamurti Kumar; Brossi Arnold; Lahiri Debomoy K; Mattson Mark P; Hoffer Barry J; Wang Yun; Greig Nigel H
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(4):1285-90.
-
2008: Becker Robert E; Greig Nigel H
Alzheimer's disease drug development: old problems require new priorities.
CNS & neurological disorders drug targets 2008;7(6):499-511.
-
2008: Lahiri Debomoy K; Zawia Nasser H; Greig Nigel H; Sambamurti Kumar; Maloney Bryan
Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model.
Biogerontology 2008;9(6):375-9.
-
2008: Becker Robert E; Greig Nigel H; Giacobini Ezio
Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
Journal of Alzheimer's disease : JAD 2008;15(2):303-25.
-
2008: Becker Robert E; Greig Nigel H
Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.
Current Alzheimer research 2008;5(4):346-57.
-
2008: Kamal Mohammad A; Klein Peter; Luo Weiming; Li Yazhou; Holloway Harold W; Tweedie David; Greig Nigel H
Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Neurochemical research 2008;33(5):745-53.
-
2007: Tweedie David; Sambamurti Kumar; Greig Nigel H
TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets.
Current Alzheimer research 2007;4(4):378-85.
-
2007: Utsuki Tadanobu; Uchimura Nao; Irikura Mitsuru; Moriuchi Hiroshi; Holloway Harold W; Yu Qian-Sheng; Spangler Edward L; Mamczarz Jacek; Ingram Donald K; Irie Tetsumi; Greig Nigel H
Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.
The Journal of pharmacology and experimental therapeutics 2007;321(1):353-61.
-
2007: Tweedie David; Milman Anat; Holloway Harold W; Li Yazhou; Harvey Brandon K; Shen Hui; Pistell Paul J; Lahiri Debomoy K; Hoffer Barry J; Wang Yun; Pick Chaim G; Greig Nigel H
Apoptotic and behavioral sequelae of mild brain trauma in mice.
Journal of neuroscience research 2007;85(4):805-15.
-
2007: Perry TracyAnn; Holloway Harold W; Weerasuriya Ananda; Mouton Peter R; Duffy Kara; Mattison Julie A; Greig Nigel H
Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.
Experimental neurology 2007;203(2):293-301.
-
2007: Lahiri Debomoy K; Chen DeMao; Maloney Bryan; Holloway Harold W; Yu Qian-sheng; Utsuki Tada; Giordano Tony; Sambamurti Kumar; Greig Nigel H
The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
The Journal of pharmacology and experimental therapeutics 2007;320(1):386-96.
-
2007: Haberman Frank; Tang Sung-Chun; Arumugam Thiruma V; Hyun Dong-Hoon; Yu Qian-Sheng; Cutler Roy G; Guo Zhihong; Holloway Harold W; Greig Nigel H; Mattson Mark P
Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice.
Neuromolecular medicine 2007;9(4):315-23.
-
2007: Lahiri Debomoy K; Alley George M; Tweedie David; Chen Demao; Greig Nigel H
Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.
Neuromolecular medicine 2007;9(2):157-68.
-
2006: Lahiri Debomoy K; Ge Yuan-Wen; Rogers Jack T; Sambamurti Kumar; Greig Nigel H; Maloney Bryan
Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factors.
Current Alzheimer research 2006;3(5):475-83.
-
2006: Kamal Mohammad A; Klein Peter; Yu Qian-Sheng; Tweedie David; Li Yazhou; Holloway Harold W; Greig Nigel H
Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
Journal of Alzheimer's disease : JAD 2006;10(1):43-51.
-
2006: Tweedie David; Brossi Arnold; Chen DeMoa; Ge Yuan-Wen; Bailey Jason; Yu Qian-Sheng; Kamal Mohammad A; Sambamurti Kumar; Lahiri Debomoy K; Greig Nigel H
Neurine, an acetylcholine autolysis product, elevates secreted amyloid-beta protein precursor and amyloid-beta peptide levels, and lowers neuronal cell viability in culture: a role in Alzheimer's disease?
Journal of Alzheimer's disease : JAD 2006;10(1):9-16.
-
2006: Utsuki Tada; Yu Qian-Sheng; Davidson Diane; Chen Demao; Holloway Harold W; Brossi Arnold; Sambamurti Kumar; Lahiri Debomoy K; Greig Nigel H; Giordano Tony
Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.
The Journal of pharmacology and experimental therapeutics 2006;318(2):855-62.
-
2006: Luo Weiming; Yu Qian-Sheng; Kulkarni Santosh S; Parrish Damon A; Holloway Harold W; Tweedie David; Shafferman Avigdor; Lahiri Debomoy K; Brossi Arnold; Greig Nigel H
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
Journal of medicinal chemistry 2006;49(7):2174-85.
-
2006: Kamal Mohammad A; Al-Jafari Abdulaziz A; Yu Qian-Sheng; Greig Nigel H
Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Biochimica et biophysica acta 2006;1760(2):200-6.
-
2006: Maloney Bryan; Ge Yuan-Wen; Greig Nigel H; Lahiri Debomoy K
Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter.
Journal of molecular neuroscience : MN 2006;29(1):81-99.
-
2005: Lahiri Debomoy K; Chen De-Mao; Lahiri Preeti; Bondy Steve; Greig Nigel H
Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases.
Annals of the New York Academy of Sciences 2005;1056():430-49.
-
2005: Greig Nigel H; Utsuki Tadanobu; Ingram Donald K; Wang Yue; Pepeu Giancarlo; Scali Carla; Yu Qian-Sheng; Mamczarz Jacek; Holloway Harold W; Giordano Tony; Chen DeMao; Furukawa Katsutoshi; Sambamurti Kumar; Brossi Arnold; Lahiri Debomoy K
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(47):17213-8.
-
2005: Greig Nigel H; Ruckle Jon; Comer Patrick; Brownell Lidia; Holloway Harold W; Flanagan Douglas R; Canfield Craig J; Burford Robert G
Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects.
Current Alzheimer research 2005;2(4):483-92.
-
2005: Luo Weiming; Yu Qian-Sheng; Holloway Harold W; Parrish Damon; Greig Nigel H; Brossi Arnold
Syntheses of tetrahydrofurobenzofurans and dihydromethanobenzodioxepines from 5-hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and ring expansion under reductive conditions on treatment with hydrides.
The Journal of organic chemistry 2005;70(16):6171-6.
-
2005: Perry Tracyann; Greig Nigel H
Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.
Current Alzheimer research 2005;2(3):377-85.
-
2005: Greig Nigel H; Sambamurti Kumar; Yu Qian-sheng; Brossi Arnold; Bruinsma Gosse B; Lahiri Debomoy K
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
Current Alzheimer research 2005;2(3):281-90.
-
2005: Carmona Gilberto N; Schindler Charles W; Greig Nigel H; Holloway Harold W; Jufer Rebecca A; Cone Edward J; Gorelick David A
Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats.
European journal of pharmacology 2005;517(3):186-90.
-
2005: Doyle Máire E; McConville Patrick; Theodorakis Michael J; Goetschkes Margaret M; Bernier Michel; Spencer Richard G S; Holloway Harold W; Greig Nigel H; Egan Josephine M
In vivo biological activity of exendin (1-30).
Endocrine 2005;27(1):1-9.
-
2005: Luo Weiming; Yu Qian-sheng; Zhan Ming; Parrish Damon; Deschamps Jeffrey R; Kulkarni Santosh S; Holloway Harold W; Alley George M; Lahiri Debomoy K; Brossi Arnold; Greig Nigel H
Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.
Journal of medicinal chemistry 2005;48(4):986-94.
-
2005: Janas Anne M; Cunningham Steven C; Duffy Kara B; Devan Bryan D; Greig Nigel H; Holloway Harold W; Yu Quian-Sheng; Markowska Alicja L; Ingram Donald K; Spangler Edward L
The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats.
Life sciences 2005;76(10):1073-81.
-
2004: Greig Nigel H; Mattson Mark P; Perry Tracyann; Chan Sic L; Giordano Tony; Sambamurti Kumar; Rogers Jack T; Ovadia Haim; Lahiri Debomoy K
New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists.
Annals of the New York Academy of Sciences 2004;1035():290-315.
-
2004: Lahiri Debomoy K; Chen Demao; Lahiri Preeti; Rogers Jack T; Greig Nigel H; Bondy Stephen
Melatonin, metals, and gene expression: implications in aging and neurodegenerative disorders.
Annals of the New York Academy of Sciences 2004;1035():216-30.
-
2004: Venti Amanda; Giordano Tony; Eder Paul; Bush Ashley I; Lahiri Debomoy K; Greig Nigel H; Rogers Jack T
The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region.
Annals of the New York Academy of Sciences 2004;1035():34-48.
-
2004: Perry Tracy Ann; Weerasuriya Ananda; Mouton Peter R; Holloway Harold W; Greig Nigel H
Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy.
Experimental neurology 2004;190(1):133-44.
-
2004: Perry Tracy Ann; Greig Nigel H
A new Alzheimer's disease interventive strategy: GLP-1.
Current drug targets 2004;5(6):565-71.
-
2004: Maloney Bryan; Ge Yuan-Wen; Greig Nigel; Lahiri Debomoy K
Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(11):1288-90.
-
2004: Lahiri Debomoy K; Greig Nigel H
Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer's disease.
Neurobiology of aging 2004;25(5):581-7.
-
2004: Greig Nigel H; Giordano Tony; Zhu Xiaoxiang; Yu Qian-sheng; Perry Tracy Ann; Holloway Harold W; Brossi Arnold; Rogers Jack T; Sambamurti Kumar; Lahiri Debomoy K
Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases.
Acta neurobiologiae experimentalis 2004;64(1):1-9.
-
2003: Lahiri D K; Chen D; Ge Y-W; Farlow M; Kotwal G; Kanthasamy A; Ingram D K; Greig N H
Does nitric oxide synthase contribute to the pathogenesis of Alzheimer's disease?: effects of beta-amyloid deposition on NOS in transgenic mouse brain with AD pathology.
Annals of the New York Academy of Sciences 2003;1010():639-42.
-
2003: Zhu Xiaoxiang; Giordano Tony; Yu Qian-Sheng; Holloway Harold W; Perry Tracy Ann; Lahiri Debomoy K; Brossi Arnold; Greig Nigel H
Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity.
Journal of medicinal chemistry 2003;46(24):5222-9.
-
2003: Perry TracyAnn; Greig Nigel H
The glucagon-like peptides: a double-edged therapeutic sword?
Trends in pharmacological sciences 2003;24(7):377-83.
-
2003: Doyle Máire E; Theodorakis Michael J; Holloway Harold W; Bernier Michel; Greig Nigel H; Egan Josephine M
The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity.
Regulatory peptides 2003;114(2-3):153-8.
-
2003: Perry TracyAnn; Lahiri Debomoy K; Sambamurti Kumar; Chen Demao; Mattson Mark P; Egan Josephine M; Greig Nigel H
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.
Journal of neuroscience research 2003;72(5):603-12.
-
2003: Lahiri D K; Chen D; Vivien D; Ge Y-W; Greig N H; Rogers J T
Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5'-UTR-binding nuclear factor and its implications in Alzheimer's disease.
Journal of Alzheimer's disease : JAD 2003;5(2):81-90.
-
2003: Lahiri Debomoy K; Farlow Martin R; Sambamurti Kumar; Greig Nigel H; Giacobini Ezio; Schneider Lon S
A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease.
Current drug targets 2003;4(2):97-112.
-
2003: Gilman Charles P; Chan Sic L; Guo Zhihong; Zhu Xiaoxiang; Greig Nigel; Mattson Mark P
p53 is present in synapses where it mediates mitochondrial dysfunction and synaptic degeneration in response to DNA damage, and oxidative and excitotoxic insults.
Neuromolecular medicine 2003;3(3):159-72.
-
2002: Perry TracyAnn; Greig Nigel H
The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease.
Journal of Alzheimer's disease : JAD 2002;4(6):487-96.
-
2002: Zhu Xiaoxiang; Yu Qian-Sheng; Cutler Roy G; Culmsee Carsten W; Holloway Harold W; Lahiri Debomoy K; Mattson Mark P; Greig Nigel H
Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives.
Journal of medicinal chemistry 2002;45(23):5090-7.
-
2002: Duan Wenzhen; Zhu Xiaoxiang; Ladenheim Bruce; Yu Qian-sheng; Guo Zhihong; Oyler Jon; Cutler Roy G; Cadet Jean Lud; Greig Nigel H; Mattson Mark P
p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism.
Annals of neurology 2002;52(5):597-606.
-
2002: Rogers Jack T; Randall Jeffrey D; Cahill Catherine M; Eder Paul S; Huang Xudong; Gunshin Hiromi; Leiter Lorene; McPhee Jay; Sarang Satinder S; Utsuki Tada; Greig Nigel H; Lahiri Debomoy K; Tanzi Rudolph E; Bush Ashley I; Giordano Tony; Gullans Steve R
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript.
The Journal of biological chemistry 2002;277(47):45518-28.
-
2002: Utsuki Tadanobu; Shoaib Mohammed; Holloway Harold W; Ingram Donald K; Wallace William C; Haroutunian Vahram; Sambamurti Kumar; Lahiri Debomoy K; Greig Nigel H
Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat.
Journal of Alzheimer's disease : JAD 2002;4(5):405-15.
-
2002: Perry TracyAnn; Haughey Norman J; Mattson Mark P; Egan Josephine M; Greig Nigel H
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
The Journal of pharmacology and experimental therapeutics 2002;302(3):881-8.
-
2002: Rogers Jack T; Randall Jeffrey D; Eder Paul S; Huang Xudong; Bush Ashley I; Tanzi Rudolph E; Venti Amanda; Payton Sandra M; Giordano Tony; Nagano Seiichi; Cahill Catherine M; Moir Robert; Lahiri Debomoy K; Greig Nigel; Sarang Satinder Singh; Gullans Steven R
Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region.
Journal of molecular neuroscience : MN 2002;19(1-2):77-82.
-
2002: Yu Qian-Sheng; Zhu Xiaoxiang; Holloway Harold W; Whittaker Noel F; Brossi Arnold; Greig Nigel H
Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
Journal of medicinal chemistry 2002;45(17):3684-91.
-
2002: Lahiri D K; Utsuki T; Chen D; Farlow M R; Shoaib M; Ingram D K; Greig N H
Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins.
Annals of the New York Academy of Sciences 2002;965():364-72.
-
2002: Perry TracyAnn; Lahiri Debomoy K; Chen Demao; Zhou Jie; Shaw Karen T Y; Egan Josephine M; Greig Nigel H
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
The Journal of pharmacology and experimental therapeutics 2002;300(3):958-66.
-
2002: Greig Nigel H; Lahiri Debomoy K; Sambamurti Kumar
Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
International psychogeriatrics / IPA 2002;14 Suppl 1():77-91.
-
2001: Yu Q; Holloway H W; Flippen-Anderson J L; Hoffman B; Brossi A; Greig N H
Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action.
Journal of medicinal chemistry 2001;44(24):4062-71.
-
2001: Doyle M E; Greig N H; Holloway H W; Betkey J A; Bernier M; Egan J M
Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
Endocrinology 2001;142(10):4462-8.
-
2001: Shaw K T; Utsuki T; Rogers J; Yu Q S; Sambamurti K; Brossi A; Ge Y W; Lahiri D K; Greig N H
Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(13):7605-10.
-
2001: Culmsee C; Zhu X; Yu Q S; Chan S L; Camandola S; Guo Z; Greig N H; Mattson M P
A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide.
Journal of neurochemistry 2001;77(1):220-8.
-
2001: Greig N H; Utsuki T; Yu Q; Zhu X; Holloway H W; Perry T; Lee B; Ingram D K; Lahiri D K
A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Current medical research and opinion 2001;17(3):159-65.
-
2000: Kamal M A; Greig N H; Alhomida A S; Al-Jafari A A
Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine.
Biochemical pharmacology 2000;60(4):561-70.
-
2000: Furey M L; Pietrini P; Alexander G E; Mentis M J; Szczepanik J; Shetty U; Greig N H; Holloway H W; Schapiro M B; Freo U
Time course of pharmacodynamic and pharmacokinetic effects of physostigmine assessed by functional brain imaging in humans.
Pharmacology, biochemistry, and behavior 2000;66(3):475-81.
-
2000: Szayna M; Doyle M E; Betkey J A; Holloway H W; Spencer R G; Greig N H; Egan J M
Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.
Endocrinology 2000;141(6):1936-41.
-
2000: Carmona G N; Jufer R A; Goldberg S R; Gorelick D A; Greig N H; Yu Q S; Cone E J; Schindler C W
Butyrylcholinesterase accelerates cocaine metabolism: in vitro and in vivo effects in nonhuman primates and humans.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(3):367-71.
-
2000: Lahiri D K; Farlow M R; Hintz N; Utsuki T; Greig N H
Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.
Acta neurologica Scandinavica. Supplementum 2000;176():60-7.
-
2000: Greig N H; De Micheli E; Holloway H W; Yu Q S; Utsuki T; Perry T A; Brossi A; Ingram D K; Deutsch J; Lahiri D K; Soncrant T T
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
Acta neurologica Scandinavica. Supplementum 2000;176():74-84.
-
1999: Yu Q; Holloway H W; Utsuki T; Brossi A; Greig N H
Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Journal of medicinal chemistry 1999;42(10):1855-61.
-
1999: Asthana S; Raffaele K C; Greig N H; Schapiro M B; Blackman M R; Soncrant T T
Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease.
Alzheimer disease and associated disorders 1999;13(2):102-8.
-
1999: Shaw K T; Greig N H
Chemokine receptor mRNA expression at the in vitro blood-brain barrier during HIV infection.
Neuroreport 1999;10(1):53-6.
-
1999: Greig N H; Holloway H W; De Ore K A; Jani D; Wang Y; Zhou J; Garant M J; Egan J M
Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Diabetologia 1999;42(1):45-50.
-
1998: Carmona G N; Schindler C W; Shoaib M; Jufer R; Cone E J; Goldberg S R; Greig N H; Yu Q S; Gorelick D A
Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase.
Experimental and clinical psychopharmacology 1998;6(3):274-9.
-
1998: al-Jafari A A; Kamal M A; Greig N H; Alhomida A S; Perry E R
Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine.
Biochemical and biophysical research communications 1998;248(1):180-5.
-
1998: Patel N; Spangler E L; Greig N H; Yu Q S; Ingram D K; Meyer R C
Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor.
Neuroreport 1998;9(1):171-6.
-
1997: Lahiri D K; Farlow M R; Nurnberger J I; Greig N H
Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.
Annals of the New York Academy of Sciences 1997;826():416-21.
-
1997: De Ore K; Greig N H; Holloway H W; Wang Y; Perfetti R; Egan J M
The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test.
The journals of gerontology. Series A, Biological sciences and medical sciences 1997;52(5):B245-9.
-
1997: Yu Q S; Pei X F; Holloway H W; Greig N H; Brossi A
Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues.
Journal of medicinal chemistry 1997;40(18):2895-901.
-
1997: Haroutunian V; Greig N; Pei X F; Utsuki T; Gluck R; Acevedo L D; Davis K L; Wallace W C
Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.
Brain research. Molecular brain research 1997;46(1-2):161-8.
-
1997: Wang Y; Perfetti R; Greig N H; Holloway H W; DeOre K A; Montrose-Rafizadeh C; Elahi D; Egan J M
Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.
The Journal of clinical investigation 1997;99(12):2883-9.
-
1996: Asthana S; Greig N H; Holloway H W; Raffaele K C; Berardi A; Schapiro M B; Rapoport S I; Soncrant T T
Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease.
Clinical pharmacology and therapeutics 1996;60(3):276-82.
-
1996: Ingram D K; Shimada A; Spangler E L; Ikari H; Hengemihle J; Kuo H; Greig N
Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems.
Annals of the New York Academy of Sciences 1996;786():348-61.
-
1995: Asthana S; Greig N H; Hegedus L; Holloway H H; Raffaele K C; Schapiro M B; Soncrant T T
Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
Clinical pharmacology and therapeutics 1995;58(3):299-309.
-
1995: Ikari H; Spangler E L; Greig N H; Pei X F; Brossi A; Speer D; Patel N; Ingram D K
Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase.
Neuroreport 1995;6(3):481-4.
-
1995: Greig N H; Pei X F; Soncrant T T; Ingram D K; Brossi A
Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease.
Medicinal research reviews 1995;15(1):3-31.
-
1995: Asthana S; Raffaele K C; Berardi A; Greig N H; Haxby J V; Schapiro M B; Soncrant T T
Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
Alzheimer disease and associated disorders 1995;9(4):223-32.
-
1995: Asthana S; Raffaele K C; Greig N H; Berardi A; Morris P P; Schapiro M B; Rapoport S I; Blackman M R; Soncrant T T
Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease.
Psychoneuroendocrinology 1995;20(6):623-36.
-
1994: Ingram D K; Spangler E L; Iijima S; Kuo H; Bresnahan E L; Greig N H; London E D
New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment.
Annals of the New York Academy of Sciences 1994;717():16-32.
-
1994: Nariai T; DeGeorge J J; Greig N H; Genka S; Rapoport S I; Purdon A D
Differences in rates of incorporation of intravenously injected radiolabeled fatty acids into phospholipids of intracerebrally implanted tumor and brain in awake rats.
Clinical & experimental metastasis 1994;12(3):213-25.
-
1994: Ingram D K; Spangler E L; Iijima S; Ikari H; Kuo H; Greig N H; London E D
Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis.
Life sciences 1994;55(25-26):2037-49.
-
1993: Nariai T; Greig N H; DeGeorge J J; Genka S; Rapoport S I
Intravenously injected radiolabelled fatty acids image brain tumour phospholipids in vivo: differential uptakes of palmitate, arachidonate and docosahexaenoate.
Clinical & experimental metastasis 1993;11(2):141-9.
-
1993: Genka S; Deutsch J; Shetty U H; Stahle P L; John V; Lieberburg I M; Ali-Osman F; Rapoport S I; Greig N H
Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil.
Clinical & experimental metastasis 1993;11(2):131-40.
-
1993: Iijima S; Greig N H; Garofalo P; Spangler E L; Heller B; Brossi A; Ingram D K
Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Psychopharmacology 1993;112(4):415-20.
-
1992: Iijima S; Greig N H; Garofalo P; Spangler E L; Heller B; Brossi A; Ingram D K
The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Neuroscience letters 1992;144(1-2):79-83.
-
1992: Deutsch J; Hegedus L; Greig N H; Rapoport S I; Soncrant T T
Electron-impact and chemical ionization detection of nicotine and cotinine by gas chromatography-mass spectrometry in rat plasma and brain.
Journal of chromatography 1992;579(1):93-8.
-
1992: Takada Y; Vistica D T; Greig N H; Purdon D; Rapoport S I; Smith Q R
Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier.
Cancer research 1992;52(8):2191-6.
-
1992: Freo U; Holloway H W; Greig N H; Soncrant T T
Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin.
Psychopharmacology 1992;107(1):30-8.
-
1991: Nariai T; DeGeorge J J; Greig N H; Rapoport S I
In vivo incorporation of [9,10(-3)H]-palmitate into a rat metastatic brain-tumor model.
Journal of neurosurgery 1991;74(4):643-9.
-
1991: Greig N H; Nariai T; Noronha J G; Schmall B; Larson D M; Soncrant T T; Rapoport S I
Brain tumor imaging in rats using the positron emitting fatty acid dl-erythro-9,10-[18F]difluoropalmitate.
Clinical & experimental metastasis 1991;9(1):67-73.
-
1991: Takada Y; Greig N H; Vistica D T; Rapoport S I; Smith Q R
Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier.
Cancer chemotherapy and pharmacology 1991;29(2):89-94.
-
1990: Greig N H; Stahle P L; Shetty H U; Genka S; John V; Soncrant T T; Rapoport S I
High-performance liquid chromatographic analysis of chlorambucil tert.-butyl ester and its active metabolites chlorambucil and phenylacetic mustard in plasma and tissue.
Journal of chromatography 1990;534():279-86.
-
1990: Phelan D G; Greig N H; Rapoport S I; Soncrant T T
High-performance liquid chromatographic assay of bromocriptine in rat plasma and brain.
Journal of chromatography 1990;533():264-70.
-
1990: Deutsch J; Soncrant T T; Greig N H; Rapoport S I
Electron-impact ionization detection of scopolamine by gas chromatography-mass spectrometry in rat plasma and brain.
Journal of chromatography 1990;528(2):325-31.
-
1990: Greig N H; Soncrant T T; Shetty H U; Momma S; Smith Q R; Rapoport S I
Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.
Cancer chemotherapy and pharmacology 1990;26(4):263-8.
-
1990: Greig N H; Daly E M; Sweeney D J; Rapoport S I
Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain.
Cancer chemotherapy and pharmacology 1990;25(5):320-5.
-
1990: Greig N H; Genka S; Daly E M; Sweeney D J; Rapoport S I
Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration.
Cancer chemotherapy and pharmacology 1990;25(5):311-9.
-
1990: Genka S; Deutsch J; Stahle P L; Shetty U H; John V; Robinson C; Rapoport S I; Greig N H
Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.
Cancer chemotherapy and pharmacology 1990;27(1):1-7.
-
1989: Soncrant T T; Holloway H W; Greig N H; Rapoport S I
Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats.
Brain research 1989;487(2):255-66.
-
1988: Greig N H; Fredericks W R; Holloway H W; Soncrant T T; Rapoport S I
Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat.
The Journal of pharmacology and experimental therapeutics 1988;245(2):581-6.
-
1988: Greig N H; Soncrant T T; Wozniak K M; Rapoport S I
Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration.
The Journal of pharmacology and experimental therapeutics 1988;245(2):574-80.
-
1988: Greig N H; Sweeney D J; Rapoport S I
Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.
Cancer chemotherapy and pharmacology 1988;21(1):1-8.
-
1987: Greig N H; Momma S; Sweeney D J; Smith Q R; Rapoport S I
Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system.
Cancer research 1987;47(6):1571-6.
-
1987: Greig N H; Sweeney D J; Rapoport S I
Melphalan concentration dependent plasma protein binding in healthy humans and rats.
European journal of clinical pharmacology 1987;32(2):179-85.
-
1985: Sweeney D J; Greig N H; Rapoport S I
High-performance liquid chromatographic analysis of melphalan in plasma, brain and peripheral tissue by o-phthalaldehyde derivatization and fluorescence detection.
Journal of chromatography 1985;339(2):434-9.
-
1985: Greig N H; Sweeney D J; Rapoport S I
Inability of dimethyl sulfoxide to increase brain uptake of water-soluble compounds: implications to chemotherapy for brain tumors.
Cancer treatment reports 1985;69(3):305-12.
Sign-in to see more
